Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Anatomy, Etiology, Management, and Medico-Legal Implications of Botulinum-induced Blepharoptosis.
Curr Rev Clin Exp Pharmacol
January 2025
Section of Legal Medicine, School of Law, University of Camerino, Camerino, 62032, Italy.
Botulinum toxin injections, a popular aesthetic treatment, have over 7.4 million beneficiaries in the U.S.
View Article and Find Full Text PDFINCUOLATION THE BOTULINUM TOXIN-B IN THE ZYGOMITICUS OF THE RAT, FOLLOWED BY EVALUATION IT'S EFFECT HISTOLOGICALLY ON THE ZYGOMATIC BONE.
Georgian Med News
November 2024
1Department of biology, College of Education for Women, University of Kirkuk, Iraq.
Background: Botulinum toxin is an attenuated neurotoxin of Clostridium Botulinum gram positive bacterial, which is used in medication sialorrhea, cervical dystonia, hyperhidrosis and non-surgical cosmetic operation (aesthetic) such as facial wrinkles and reduced the bulky appearance hypertrophied of masseter muscle. This study was designed to revealed the effect of zygomiticus inoculation of botulinum toxin B in zygomatic muscle of rats on zygomatic bone.
Methods: A total of 25 male albino rats (200-260 gm) were injected facial intramuscular by a single dose of 2.
Delphi Consensus on the Management of Spanish Patients with Post-Stroke Hemiplegic Shoulder Pain Treated with Botulinum Toxin A: Result Study.
Toxins (Basel)
January 2025
Doctor Negrín University Hospital of Gran Canaria, Pl. Barranco de la Ballena s/n, 35010 Las Palmas de Gran Canaria, Spain.
The study aimed to identify expert opinions and obtain recommendations on the management of post-stroke hemiplegic shoulder pain (HSP) and treatment with botulinum toxin A (BoNT-A). A multicenter Delphi study was conducted using an online survey designed by a committee of experts with at least 10 years of experience in post-stroke HSP management with BoNT-A in Spain. Forty-seven panelists (specialists with at least 5 years of experience in post-stroke HSP management with BoNT-A) rated their level of agreement in two rounds based on acceptance by ≥66.
View Article and Find Full Text PDFA Study of Combined Onabotulinumtoxin A and Hyaluronic Acid Filler for the Treatment of Enlarged Facial Pores.
Toxins (Basel)
January 2025
Division of Dermatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.
Introduction: Enlarged facial pores are a common cosmetic concern caused by excessive sebum production, visible hair shafts, and a reduction in skin elasticity, leading to a decrease in skin quality and overall appearance. Various treatment modalities have been explored to address this issue. This study focuses on the efficacy and safety of combining Onabotulinumtoxin A (OnaBoNT-A) and hyaluronic acid filler (HA filler) to target enlarged facial pores in Asians.
View Article and Find Full Text PDFTreatment Crossover Following Advanced Therapy for Overactive Bladder Syndrome.
Urogynecology (Phila)
February 2025
From the Departments of Gynecology and Obstetrics.
Importance: Patients deciding between advanced therapies for overactive bladder syndrome may be interested to know the likelihood of treatment crossover after sacral neuromodulation, intradetrusor OnabotulinumtoxinA, or percutaneous tibial nerve stimulation. Treatment crossover was defined as a switch from one advanced therapy to another.
Objectives: The aim of this study was to estimate the rate of treatment crossover after each advanced therapy for nonneurogenic overactive bladder syndrome.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!